Genocea Biosciences (GNCA) Tops Q2 EPS by 1c

Genocea Biosciences (NASDAQ: GNCA) reported Q2 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40).

“We continue to advance our clinical programs for patients living with cancer,” said Chip Clark, President and Chief Executive Officer, Genocea. “I am pleased by our ability to remain on track during these uncertain times, meeting our highest priority milestones and working to deliver on the promise of developing effective immunotherapies through our unique and differentiated approach.”

Guidance
Genocea expects that its existing cash and cash equivalents inclusive of the private placement proceeds are sufficient to support its operations to mid-2022.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
• HubSpot chief legal officer to resign in November
• TD Cowen on Pepsico (PEP): 'Ongoing Weakness in North America Drives Guidance Cut'